New drug targets Hard-to-Treat cancers by homing in on a specific protein
NCT ID NCT05857332
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This study tests an experimental drug called SG1906 in people with advanced solid tumors that have a specific protein (CLDN18.2) on their surface. The trial has two parts: first, finding the safest dose, and then checking for early signs that the drug can shrink tumors. About 60 adults whose cancer has spread or cannot be removed by surgery are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SG1906
- What this could lead to
- If safe and effective, SG1906 could offer a new treatment option for people with advanced cancers that have a specific marker called CLDN18.2.
- What could go wrong
- This is a very early (Phase 1) trial with only 60 participants, so the main goal is safety, not proof of effectiveness. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLDN18.2-POSITIVE LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100039, China
Contact
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450003, China
Contact
-
Liaoning Cancer Hospital
RECRUITINGShenyang, Liaoning, 110801, China
Contact
-
Shanxi Cancer Hospital
RECRUITINGTaiyuan, Shanxi, 030013, China
Contact
-
The First Affiliated Hospital Of Xiamen University
RECRUITINGXiamen, Fujian, China
Contact
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110002, China
Contact
Contact
-
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact
-
The Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510655, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.